Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NRSN
Upturn stock ratingUpturn stock rating

Neurosense Therapeutics Ltd (NRSN)

Upturn stock ratingUpturn stock rating
$1.17
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: NRSN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.75

1 Year Target Price $10.75

Analysts Price Target For last 52 week
$10.75 Target price
52w Low $0.67
Current$1.17
52w High $2.6

Analysis of Past Performance

Type Stock
Historic Profit -29.71%
Avg. Invested days 27
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 28.78M USD
Price to earnings Ratio -
1Y Target Price 10.75
Price to earnings Ratio -
1Y Target Price 10.75
Volume (30-day avg) 3
Beta 1.62
52 Weeks Range 0.67 - 2.60
Updated Date 08/15/2025
52 Weeks Range 0.67 - 2.60
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.36

Earnings Date

Report Date 2025-08-01
When -
Estimate -0.225
Actual -0.09

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -303.9%
Return on Equity (TTM) -2478.16%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 25479813
Price to Sales(TTM) -
Enterprise Value 25479813
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.16
Shares Outstanding 24602400
Shares Floating 12538862
Shares Outstanding 24602400
Shares Floating 12538862
Percent Insiders 30.21
Percent Institutions 0.74

ai summary icon Upturn AI SWOT

Neurosense Therapeutics Ltd

stock logo

Company Overview

overview logo History and Background

Neurosense Therapeutics Ltd. is a biotechnology company focused on discovering and developing treatments for neurodegenerative diseases. Founded in 2016 and went IPO in 2020, it has milestones in progressing pipeline candidates through preclinical and early-stage clinical trials.

business area logo Core Business Areas

  • Drug Development: Focuses on identifying and developing novel therapeutics for diseases like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's.
  • Preclinical and Clinical Trials: Conducts research and clinical trials to evaluate the safety and efficacy of their drug candidates.
  • Intellectual Property: Secures and maintains patents and other intellectual property rights to protect their drug candidates.

leadership logo Leadership and Structure

The company's leadership team includes a CEO, CSO, and other executives with experience in drug development and the pharmaceutical industry. The organizational structure is typical of a biotechnology company, with departments focused on research, development, clinical trials, and business operations.

Top Products and Market Share

overview logo Key Offerings

  • PrimeC: An investigational drug candidate for ALS. It is in Phase II clinical trials. Currently no market share information exists. Competitors include Mitsubishi Tanabe Pharma (Radicava), Amylyx Pharmaceuticals (Relyvrio) and Biogen (Tofersen).
  • CogniTune: An investigational drug candidate for Alzheimer's disease and related cognitive impairment. Preclinical development stage. Currently no market share information exists. Competitors include Biogen (Aduhelm, Leqembi), Eli Lilly (Donanemab)

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is experiencing advancements in targeted therapeutics and personalized medicine, while facing challenges such as regulatory hurdles and competition. The Alzheimer's and ALS segments are particularly active, with unmet medical needs driving innovation.

Positioning

Neurosense is positioned as a biotechnology company developing novel therapeutics for neurodegenerative diseases, with a focus on innovative approaches.

Total Addressable Market (TAM)

The total addressable market for neurodegenerative disease therapies is estimated to be in the tens of billions of dollars. The TAM grows as the population ages. Neurosense Therapeutics is positioned to capture a portion of this TAM through its innovative drug candidates.

Upturn SWOT Analysis

Strengths

  • Novel drug candidates in development
  • Focus on unmet medical needs
  • Experienced leadership team
  • Strong intellectual property position

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • Early-stage company
  • Limited commercial infrastructure

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Successful clinical trial results
  • Expansion into new therapeutic areas
  • Government funding and grants

Threats

  • Clinical trial failures
  • Competition from larger pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • ABBV
  • BIIB
  • LLY
  • AMTX

Competitive Landscape

Neurosense faces significant competition from established pharmaceutical companies with greater resources. Neurosense's competitive advantage lies in its novel drug candidates and innovative approach.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is dependent on clinical trial advancement and partnership development.

Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections are not readily available.

Recent Initiatives: Neurosense is currently engaged in clinical trials for PrimeC and preclinical work for CogniTune

Summary

Neurosense Therapeutics is a biotechnology company with promising drug candidates in development for neurodegenerative diseases. While the company faces risks associated with clinical trials and competition, it also has opportunities to partner with larger companies and expand its pipeline. Its success hinges on the success of PrimeC and other therapeutic compounds. The company needs to focus on securing funding, advancing products in clinical trials, and establishing strategic partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • Public SEC Filings
  • Industry Reports

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are based on available data and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Neurosense Therapeutics Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-12-09
Co-Founder, CEO & Director Mr. Alon Ben-Noon
Sector Healthcare
Industry Biotechnology
Full time employees 17
Full time employees 17

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.